These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 21737909

  • 1. Rheumatoid arthritis associated with the use of Sandostatin® LAR® depot in a patient with pancreatic neuroendocrine tumor. An association or a coincidence? The first case report.
    Saif MW.
    JOP; 2011 Jul 08; 12(4):425-8. PubMed ID: 21737909
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
    Faggiano A, Tavares LB, Tauchmanova L, Milone F, Mansueto G, Ramundo V, De Caro ML, Lombardi G, De Rosa G, Colao A.
    Clin Endocrinol (Oxf); 2008 Nov 08; 69(5):756-62. PubMed ID: 18485119
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Al-Efraij K, Aljama MA, Kennecke HF.
    Cancer Med; 2015 Jun 08; 4(6):864-70. PubMed ID: 25727756
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C, Garland J, Marelli L, Srirajaskanthan R, Soh J, Davies P, Buscombe J, Caplin ME.
    Aliment Pharmacol Ther; 2009 Oct 08; 30(7):733-40. PubMed ID: 19573169
    [Abstract] [Full Text] [Related]

  • 10. Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR: a systematic literature review.
    Broder MS, Beenhouwer D, Strosberg JR, Neary MP, Cherepanov D.
    World J Gastroenterol; 2015 Feb 14; 21(6):1945-55. PubMed ID: 25684964
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
    Jallad RS, Musolino NR, Salgado LR, Bronstein MD.
    Clin Endocrinol (Oxf); 2005 Aug 14; 63(2):168-75. PubMed ID: 16060910
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Current alternative in the pharmacotherapy of acromegaly: the long-acting somatostatin analogue octreotide].
    Laczi F, Magony S, Julesz J.
    Orv Hetil; 2002 May 12; 143(19 Suppl):1062-6. PubMed ID: 12063861
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.
    Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, Reynolds N, Caplin ME.
    Aliment Pharmacol Ther; 2003 Feb 12; 17(3):437-44. PubMed ID: 12562458
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-acting octreotide for the treatment and symptomatic relief of bowel obstruction in advanced ovarian cancer.
    Matulonis UA, Seiden MV, Roche M, Krasner C, Fuller AF, Atkinson T, Kornblith A, Penson R.
    J Pain Symptom Manage; 2005 Dec 12; 30(6):563-9. PubMed ID: 16376743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.